1. World Health Organization. Dengue and severe dengue fact sheet. WHO.

Available
at http://www.who.int/mediacentre/factsheets/fs117/en/. April 2017; Accessed: September 28,
2017.

2. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. The global distribution
and burden of dengue. Nature. 2013 Apr 25. 496 (7446):504-7. [Medline].

3. Brady OJ, Gething PW, Bhatt S, Messina JP, Brownstein JS, Hoen AG, et al. Refining the global
spatial limits of dengue virus transmission by evidence-based consensus. PLoS Negl Trop Dis.
2012. 6 (8):e1760. [Medline].

4. Wilson ME, Chen LH. Dengue: update on epidemiology. Curr Infect Dis Rep. 2015 Jan. 17
(1):457. [Medline].

5. Ten threats to global health in 2019. World Health Organization. Available

at https://www.who.int/emergencies/ten-threats-to-global-health-in-2019. 2019; Accessed: Feb
2, 2019.

6. Kyle JL, Harris E. Global spread and persistence of dengue. Annu Rev Microbiol. 2008. 62:71-
92. [Medline].

7. Statler J, Mammen M, Lyons A, Sun W. Sonographic findings of healthy volunteers infected with
dengue virus. J Clin Ultrasound. 2008 Sep. 36(7):413-7. [Medline].

8. Gubler DJ. Cities spawn epidemic dengue viruses. Nat Med. 2004 Feb. 10(2):129-30. [Medline].

9. Wilder-Smith A, Gubler DJ. Geographic expansion of dengue: the impact of international

travel. Med Clin North Am. 2008 Nov. 92(6):1377-90, x. [Medline].

10. Messina JP, Brady OJ, Scott TW, Zou C, Pigott DM, Duda KA, et al. Global spread of dengue virus
types: mapping the 70 year history. Trends Microbiol. 2014 Mar. 22 (3):138-46. [Medline]. [Full
Text].

11. Halstead SB. Dengue. Lancet. 2007 Nov 10. 370(9599):1644-52. [Medline].

12. Chowell G, Torre CA, Munayco-Escate C, Suárez-Ognio L, López-Cruz R, Hyman JM. Spatial and
temporal dynamics of dengue fever in Peru: 1994-2006. Epidemiol Infect. 2008 Dec.
136(12):1667-77. [Medline].

13. Osterwell N. Dengue 'Under-recognized' as Source of Febrile Illness in US. Medscape Medical
News. Jan 23 2014. Available at http://www.medscape.com/viewarticle/819656. Accessed:
January 25, 2014.

14. Sharp TM, Gaul L, Muehlenbachs A, Hunsperger E, Bhatnagar J, Lueptow R, et al. Fatal
hemophagocytic lymphohistiocytosis associated with locally acquired dengue virus infection -
new Mexico and Texas, 2012. MMWR Morb Mortal Wkly Rep. 2014 Jan 24. 63(3):49-
54. [Medline].

15. Freedman DO, Weld LH, Kozarsky PE, Fisk T, Robins R, von Sonnenburg F. Spectrum of disease
and relation to place of exposure among ill returned travelers. N Engl J Med. 2006 Jan 12.
354(2):119-30. [Medline].
16. Liu-Helmersson J, Quam M, Wilder-Smith A, Stenlund H, Ebi K, Massad E, et al. Climate Change
and Aedes Vectors: 21st Century Projections for Dengue Transmission in Europe. EBioMedicine.
2016 May. 7:267-77. [Medline].

17. CDC. Imported dengue--United States, 1997 and 1998. MMWR Morb Mortal Wkly Rep. 2000
Mar 31. 49(12):248-53. [Medline]. [Full Text].

18. Engelthaler DM, Fink TM, Levy CE, Leslie MJ. The reemergence of Aedes aegypti in
Arizona. Emerg Infect Dis. 1997 Apr-Jun. 3(2):241-2. [Medline]. [Full Text].

19. Chye JK, Lim CT, Ng KB, et al. Vertical transmission of dengue. Clin Infect Dis. 1997 Dec.
25(6):1374-7. [Medline].

20. Wagner D, de With K, Huzly D, Hufert F, Weidmann M, Breisinger S, et al. Nosocomial acquisition
of dengue. Emerg Infect Dis. 2004 Oct. 10(10):1872-3. [Medline].

21. Dejnirattisai W, Duangchinda T, Lin CL, Vasanawathana S, Jones M, Jacobs M, et al. A complex
interplay among virus, dendritic cells, T cells, and cytokines in dengue virus infections. J
Immunol. 2008 Nov 1. 181(9):5865-74. [Medline].

22. Halstead SB, Heinz FX, Barrett AD, Roehrig JT. Dengue virus: molecular basis of cell entry and
pathogenesis, 25-27 June 2003, Vienna, Austria. Vaccine. 2005 Jan 4. 23(7):849-56. [Medline].

23. Limjindaporn T, Wongwiwat W, Noisakran S, Srisawat C, Netsawang J, Puttikhunt C, et al.

Interaction of dengue virus envelope protein with endoplasmic reticulum-resident chaperones
facilitates dengue virus production. Biochem Biophys Res Commun. 2009 Feb 6. 379(2):196-
200. [Medline].

24. Zhang JL, Wang JL, Gao N, Chen ZT, Tian YP, An J. Up-regulated expression of beta3 integrin
induced by dengue virus serotype 2 infection associated with virus entry into human dermal
microvascular endothelial cells. Biochem Biophys Res Commun. 2007 May 11. 356(3):763-
8. [Medline].

25. Rothman AL, Ennis FA. Immunopathogenesis of Dengue hemorrhagic fever. Virology. 1999 Apr
25. 257(1):1-6. [Medline].

26. Chen LC, Lei HY, Liu CC, Shiesh SC, Chen SH, Liu HS. Correlation of serum levels of macrophage
migration inhibitory factor with disease severity and clinical outcome in dengue patients. Am J
Trop Med Hyg. 2006 Jan. 74(1):142-7. [Medline].

27. Green S, Rothman A. Immunopathological mechanisms in dengue and dengue hemorrhagic

fever. Curr Opin Infect Dis. 2006 Oct. 19(5):429-36. [Medline].

28. Guzman MG, Alvarez M, Rodriguez-Roche R, Bernardo L, Montes T, Vazquez S. Neutralizing

antibodies after infection with dengue 1 virus. Emerg Infect Dis. 2007 Feb. 13(2):282-
6. [Medline].

29. Restrepo BN, Ramirez RE, Arboleda M, Alvarez G, Ospina M, Diaz FJ. Serum levels of cytokines in
two ethnic groups with dengue virus infection. Am J Trop Med Hyg. 2008 Nov. 79(5):673-
7. [Medline].
30. Rothman AL. Dengue: defining protective versus pathologic immunity. J Clin Invest. 2004 Apr.
113(7):946-51. [Medline].

31. de Macedo FC, Nicol AF, Cooper LD, Yearsley M, Pires AR, Nuovo GJ. Histologic, viral, and
molecular correlates of dengue fever infection of the liver using highly sensitive
immunohistochemistry. Diagn Mol Pathol. 2006 Dec. 15(4):223-8. [Medline].

32. Shah I. Dengue and liver disease. Scand J Infect Dis. 2008. 40(11-12):993-4. [Medline].

33. Dejnirattisai W, Jumnainsong A, Onsirisakul N, et al. Cross-reacting antibodies enhance dengue

virus infection in humans. Science. 2010 May 7. 328(5979):745-8. [Medline].

34. Schmidt AC. Response to dengue fever--the good, the bad, and the ugly?. N Engl J Med. 2010 Jul
29. 363(5):484-7. [Medline].

35. Kurane I, Innis BL, Nimmannitya S, Nisalak A, Meager A, Ennis FA. High levels of interferon alpha
in the sera of children with dengue virus infection. Am J Trop Med Hyg. 1993 Feb. 48(2):222-
9. [Medline].

36. Ojha A, Nandi D, Batra H, Singhal R, Annarapu GK, Bhattacharyya S, et al. Platelet activation
determines the severity of thrombocytopenia in dengue infection. Sci Rep. 2017 Jan 31.
7:41697. [Medline].

37. Hottz ED, Oliveira MF, Nunes PC, Nogueira RM, Valls-de-Souza R, Da Poian AT, et al. Dengue
induces platelet activation, mitochondrial dysfunction and cell death through mechanisms that
involve DC-SIGN and caspases. J Thromb Haemost. 2013 May. 11 (5):951-62. [Medline].

38. Wang E, Ni H, Xu R, Barrett AD, Watowich SJ, Gubler DJ. Evolutionary relationships of
endemic/epidemic and sylvatic dengue viruses. J Virol. 2000 Apr. 74(7):3227-34. [Medline].

39. Centers for Disease Control and Prevention Web site. CDC traveler's health page. Dengue.
Available at http://www.cdc.gov/Dengue/travelOutbreaks/. Accessed: October 20, 2011.

40. Chen WS, Wong CH, Cillekens L. Dengue antibodies in a suburban community in Malaysia. Med J
Malaysia. 2003 Mar. 58(1):142-3. [Medline].

41. Istúriz RE, Gubler DJ, Brea del Castillo J. Dengue and dengue hemorrhagic fever in Latin America
and the Caribbean. Infect Dis Clin North Am. 2000 Mar. 14(1):121-40, ix. [Medline].

42. Hotez PJ, Bottazzi ME, Franco-Paredes C, Ault SK, Periago MR. The neglected tropical diseases of
Latin America and the Caribbean: a review of disease burden and distribution and a roadmap for
control and elimination. PLoS Negl Trop Dis. 2008 Sep 24. 2(9):e300. [Medline]. [Full Text].

43. Centers for Disease Control and Prevention (CDC). Travel-associated Dengue surveillance -
United States, 2006-2008. MMWR Morb Mortal Wkly Rep. 2010 Jun 18. 59(23):715-
9. [Medline]. [Full Text].

44. Centers for Disease Control and Prevention (CDC). Locally acquired Dengue--Key West, Florida,
2009-2010. MMWR Morb Mortal Wkly Rep. 2010 May 21. 59(19):577-81. [Medline].

45. Rey JR. Dengue in Florida (USA). Insects. 2014 Dec 16. 5 (4):991-1000. [Medline].
46. Malavige GN, Fernando S, Fernando DJ, Seneviratne SL. Dengue viral infections. Postgrad Med J.
2004 Oct. 80(948):588-601. [Medline]. [Full Text].

47. Stephenson JR. Understanding dengue pathogenesis: implications for vaccine design. Bull World
Health Organ. 2005 Apr. 83(4):308-14. [Medline]. [Full Text].

48. World Health Organization. Impact of Dengue. Available

at http://www.who.int/csr/disease/dengue/impact/en/index.html. Accessed: October 14, 2011.

49. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. The global distribution
and burden of dengue. Nature. 2013 Apr 25. 496 (7446):504-7. [Medline].

50. Brady OJ, Gething PW, Bhatt S, Messina JP, Brownstein JS, Hoen AG, et al. Refining the global
spatial limits of dengue virus transmission by evidence-based consensus. PLoS Negl Trop Dis.
2012. 6 (8):e1760. [Medline].

51. Lin CC, Huang YH, Shu PY, et al. Characteristic of dengue disease in Taiwan: 2002-2007. Am J
Trop Med Hyg. 2010 Apr. 82(4):731-9. [Medline]. [Full Text].

52. Anderson KB, Chunsuttiwat S, Nisalak A, Mammen MP, Libraty DH, Rothman AL. Burden of
symptomatic dengue infection in children at primary school in Thailand: a prospective
study. Lancet. 2007 Apr 28. 369(9571):1452-9. [Medline].

53. Anker M, Arima Y. Male-female differences in the number of reported incident dengue fever
cases in six Asian countries. Western Pac Surveill Response J. 2011 Apr. 2 (2):17-23. [Medline].

54. Lahiri M, Fisher D, Tambyah PA. Dengue mortality: reassessing the risks in transition
countries. Trans R Soc Trop Med Hyg. 2008 Oct. 102(10):1011-6. [Medline].

55. Beatty ME, Beutels P, Meltzer MI, et al. Health economics of dengue: a systematic literature
review and expert panel's assessment. Am J Trop Med Hyg. 2011 Mar. 84(3):473-
88. [Medline]. [Full Text].

56. Shepard DS, Coudeville L, Halasa YA, Zambrano B, Dayan GH. Economic impact of dengue illness
in the Americas. Am J Trop Med Hyg. 2011 Feb. 84(2):200-7. [Medline]. [Full Text].

57. Suaya JA, Shepard DS, Siqueira JB, et al. Cost of dengue cases in eight countries in the Americas
and Asia: a prospective study. Am J Trop Med Hyg. 2009 May. 80(5):846-55. [Medline].

58. WHO. Dengue haemorrhagic fever: diagnosis, treatment, prevention and control. World Health
Organization. 1997. Available at http://www.who.int/topics/dengue/en/.

59. Sanjay S, Wagle AM, Au Eong KG. Dengue optic neuropathy. Ophthalmology. 2009 Jan.
116(1):170; author reply 170. [Medline].

60. Teves Maria A. Wrong treatment most common cause of dengue fatality. ABS/CBN News.
Available at http://www.abs-cbnnews.com/nation/09/03/09/wrong-treatment-most-common-
cause-dengue-fatality. Accessed: September 3, 2010.
61. Bottieau E, Clerinx J, Van den Enden E, Van Esbroeck M, Colebunders R, Van Gompel A. Fever
after a stay in the tropics: diagnostic predictors of the leading tropical conditions. Medicine
(Baltimore). 2007 Jan. 86(1):18-25. [Medline].

62. Malhotra N, Chanana C, Kumar S. Dengue infection in pregnancy. Int J Gynaecol Obstet. 2006
Aug. 94(2):131-2. [Medline].

63. Singh N, Sharma KA, Dadhwal V, Mittal S, Selvi AS. A successful management of dengue fever in
pregnancy: report of two cases. Indian J Med Microbiol. 2008 Oct-Dec. 26(4):377-80. [Medline].

64. Warrilow D, Northill JA, Pyke A, Smith GA. Single rapid TaqMan fluorogenic probe based PCR
assay that detects all four dengue serotypes. J Med Virol. 2002 Apr. 66(4):524-8. [Medline].

65. Kong YY, Thay CH, Tin TC, Devi S. Rapid detection, serotyping and quantitation of dengue viruses
by TaqMan real-time one-step RT-PCR. J Virol Methods. 2006 Dec. 138(1-2):123-30. [Medline].

66. Trung DT, Thao le TT, Hien TT, et al. Liver involvement associated with dengue infection in adults
in Vietnam. Am J Trop Med Hyg. 2010 Oct. 83(4):774-80. [Medline]. [Full Text].

67. Potts JA, Rothman AL. Clinical and laboratory features that distinguish dengue from other febrile
illnesses in endemic populations. Trop Med Int Health. 2008 Nov. 13(11):1328-
40. [Medline]. [Full Text].

68. Lima EQ, Nogueira ML. Viral hemorrhagic fever-induced acute kidney injury. Semin Nephrol.
2008 Jul. 28(4):409-15. [Medline].

69. Lombardi R, Yu L, Younes-Ibrahim M, Schor N, Burdmann EA. Epidemiology of acute kidney

injury in Latin America. Semin Nephrol. 2008 Jul. 28(4):320-9. [Medline].

70. Chaterji S, Allen JC Jr, Chow A, Leo YS, Ooi EE. Evaluation of the NS1 rapid test and the WHO
dengue classification schemes for use as bedside diagnosis of acute dengue fever in adults. Am J
Trop Med Hyg. 2011 Feb. 84(2):224-8. [Medline]. [Full Text].

71. Wichmann O, Stark K, Shu PY, Niedrig M, Frank C, Huang JH. Clinical features and pitfalls in the
laboratory diagnosis of dengue in travellers. BMC Infect Dis. 2006. 6:120. [Medline].

72. Domingo C, de Ory F, Sanz JC, Reyes N, Gascón J, Wichmann O, et al. Molecular and serologic
markers of acute dengue infection in naive and flavivirus-vaccinated travelers. Diagn Microbiol
Infect Dis. 2009 Sep. 65(1):42-8. [Medline].

73. Srikiatkhachorn A, Krautrachue A, Ratanaprakarn W, Wongtapradit L, Nithipanya N,

Kalayanarooj S. Natural history of plasma leakage in dengue hemorrhagic fever: a serial
ultrasonographic study. Pediatr Infect Dis J. 2007 Apr. 26(4):283-90; discussion 291-2. [Medline].

74. Santhosh VR, Patil PG, Srinath MG, Kumar A, Jain A, Archana M. Sonography in the diagnosis and
assessment of dengue Fever. J Clin Imaging Sci. 2014. 4:14. [Medline]. [Full Text].

75. Srikiatkhachorn A, Gibbons RV, Green S, et al. Dengue hemorrhagic fever: the sensitivity and
specificity of the world health organization definition for identification of severe cases of dengue
in Thailand, 1994-2005. Clin Infect Dis. 2010 Apr 15. 50(8):1135-43. [Medline]. [Full Text].
76. Setiati TE, Mairuhu AT, Koraka P, Supriatna M, Mac Gillavry MR, Brandjes DP, et al. Dengue
disease severity in Indonesian children: an evaluation of the World Health Organization
classification system. BMC Infect Dis. 2007 Mar 26. 7:22. [Medline]. [Full Text].

77. Tassniyom S, Vasanawathana S, Chirawatkul A, Rojanasuphot S. Failure of high-dose

methylprednisolone in established dengue shock syndrome: a placebo-controlled, double-blind
study. Pediatrics. 1993 Jul. 92(1):111-5. [Medline].

78. WHO. Dengue. Available at http://www.who.int/topics/dengue/en/. Accessed: October 20,

2011.

79. Wills BA, Nguyen MD, Ha TL, Dong TH, Tran TN, Le TT, et al. Comparison of three fluid solutions
for resuscitation in dengue shock syndrome. N Engl J Med. 2005 Sep 1. 353(9):877-
89. [Medline].

80. Yadav SP, Sachdeva A, Gupta D, Sharma SD, Kharya G. Control of massive bleeding in dengue
hemorrhagic fever with severe thrombocytopenia by use of intravenous anti-D globulin. Pediatr
Blood Cancer. 2008 Dec. 51(6):812-3. [Medline].

81. Waduge R, Malavige GN, Pradeepan M, Wijeyaratne CN, Fernando S, Seneviratne SL. Dengue
infections during pregnancy: a case series from Sri Lanka and review of the literature. J Clin Virol.
2006 Sep. 37(1):27-33. [Medline].

82. Ismail NA, Kampan N, Mahdy ZA, Jamil MA, Razi ZR. Dengue in pregnancy. Southeast Asian J
Trop Med Public Health. 2006 Jul. 37(4):681-3. [Medline].

83. Billingsley PF, Foy B, Rasgon JL. Mosquitocidal vaccines: a neglected addition to malaria and
dengue control strategies. Trends Parasitol. 2008 Sep. 24(9):396-400. [Medline].

84. Erlanger TE, Keiser J, Utzinger J. Effect of dengue vector control interventions on entomological
parameters in developing countries: a systematic review and meta-analysis. Med Vet Entomol.
2008 Sep. 22(3):203-21. [Medline].

85. Kay B, Vu SN. New strategy against Aedes aegypti in Vietnam. Lancet. 2005 Feb 12-18.
365(9459):613-7. [Medline].

86. Hanh TT, Hill PS, Kay BH, Quy TM. Development of a framework for evaluating the sustainability
of community-based dengue control projects. Am J Trop Med Hyg. 2009 Feb. 80(2):312-
8. [Medline].

87. Hoffmann AA, Montgomery BL, Popovici J, Iturbe-Ormaetxe I, Johnson PH, Muzzi F, et al.
Successful establishment of Wolbachia in Aedes populations to suppress dengue
transmission. Nature. 2011 Aug 24. 476 (7361):454-7. [Medline].

88. Lang J. Recent progress on sanofi pasteur's dengue vaccine candidate. J Clin Virol. 2009 Oct. 46
Suppl 2:S20-4. [Medline].

89. World Health Organization. Dengue vaccine: WHO position paper – July 2016. Wkly Epidemiol
Rec. 2016 Jul 29. 91 (30):349-64. [Medline].
90. Aguiar M, Stollenwerk N, Halstead SB. The risks behind Dengvaxia recommendation. Lancet
Infect Dis. 2016 Aug. 16 (8):882-3. [Medline]. [Full Text].

91. Dengvaxia. European Medicines Agency. Available

at https://www.ema.europa.eu/en/medicines/human/EPAR/dengvaxia. 2018 Dec 18; Accessed:
Feb 15, 2019.

92. Dengvaxia (dengue vaccine) [package insert]. Swiftwater, PA: Sanofi Pasteur, Inc. May 2019.
Available at [Full Text].

93. Monath TP. Dengue and yellow fever--challenges for the development and use of vaccines. N
Engl J Med. 2007 Nov 29. 357(22):2222-5. [Medline].

94. McArthur JH, Durbin AP, Marron JA, Wanionek KA, Thumar B, Pierro DJ, et al. Phase I clinical
evaluation of rDEN4Delta30-200,201: a live attenuated dengue 4 vaccine candidate designed for
decreased hepatotoxicity. Am J Trop Med Hyg. 2008 Nov. 79(5):678-84. [Medline]. [Full Text].

95. O'Brien J. 12th Annual Conference on Vaccine Research. Expert Rev Vaccines. 2009 Sep.
8(9):1139-42. [Medline].

96. Edelman R. Dengue vaccines approach the finish line. Clin Infect Dis. 2007 Jul 15. 45 Suppl 1:S56-
60. [Medline].

97. Blaney JE Jr, Durbin AP, Murphy BR, Whitehead SS. Development of a live attenuated dengue
virus vaccine using reverse genetics. Viral Immunol. 2006 Spring. 19(1):10-32. [Medline].

98. Questions and Answers on Dengue Vaccines. World Health Organization. Available
at https://www.who.int/immunization/research/development/dengue_q_and_a/en/. 2018 April
20; Accessed: February 10, 2019.

99. Larsen CP, Whitehead SS, Durbin AP. Dengue human infection models to advance dengue
vaccine development. Vaccine. 2015 Sep 28. [Medline].

100. Anker M, Arima Y. Male-female differences in the number of reported incident dengue
fever cases in six Asian countries. Western Pac Surveill Response J. 2011 Apr. 2 (2):17-
23. [Medline].

101. R. Chen and N. Vasilakis, “Dengue-Quo Tu et Quo Vadis?” Viruses, vol. 3, no. 9, pp.
1562–1608, 2011.View at: Publisher Site | Google Scholar

102. B. R. Murphy and S. S. Whitehead, “Immune response to dengue virus and prospects for
a vaccine,” Annual Review of Immunology, vol. 29, pp. 587–619, 2011.View at: Publisher
Site | Google Scholar

103. D. J. Gubler, “Dengue/dengue haemorrhagic fever: history and current status,” Novartis

Foundation Symposium, vol. 277, pp. 3–16, 2006.View at: Publisher Site | Google Scholar
104. Sanofi Pasteur Media Release, http://www.sanofipasteur.com/en/articles/First-
Vaccinations-against-Dengue-Mark-Historic-Moment-in-Prevention-of-Infectious-Diseases.aspx.

105. World Health Organization, Dengue: Guidelines for Diagnosis, Treatment, Prevention

and Control, WHO, Geneva, Switzerland, 2009.

106. S. Bhatt, P. W. Gething, O. J. Brady et al., “The global distribution and burden of
dengue,” Nature, vol. 496, no. 7446, pp. 504–507, 2013.View at: Publisher Site | Google Scholar

107. O. J. Brady, P. W. Gething, S. Bhatt et al., “Refining the global spatial limits of dengue
virus transmission by evidence-based consensus,” PLoS Neglected Tropical Diseases, vol. 6, no.
8, Article ID e1760, 2012.View at: Publisher Site | Google Scholar

108. G. N. Malavige, S. Fernando, D. J. Fernando, and S. L. Seneviratne, “Dengue viral

infections,” Postgraduate Medical Journal, vol. 80, no. 948, pp. 588–601, 2004.View
at: Publisher Site | Google Scholar

109. J. D. Stanaway, D. S. Shepard, E. A. Undurraga et al., “The global burden of dengue: an

analysis from the Global Burden of Disease Study 2013,” The Lancet Infectious Diseases, vol.
16, no. 6, pp. 712–723, 2016.View at: Publisher Site | Google Scholar

110. G. Rezza, “Aedes albopictus and the reemergence of dengue,” BMC Public Health, vol.
12, article 72, 2012.View at: Publisher Site | Google Scholar

111. R. Perera and R. J. Kuhn, “Structural proteomics of dengue virus,” Current Opinion in

Microbiology, vol. 11, no. 4, pp. 369–377, 2008.View at: Publisher Site | Google Scholar

112. S. Apte-Sengupta, D. Sirohi, and R. J. Kuhn, “Coupling of replication and assembly in

flaviviruses,” Current Opinion in Virology, vol. 9, pp. 134–142, 2014.View at: Publisher
Site | Google Scholar

113. R. J. Kuhn, W. Zhang, M. G. Rossmann et al., “Structure of dengue virus: implications

for flavivirus organization, maturation, and fusion,” Cell, vol. 108, no. 5, pp. 717–725,
2002.View at: Publisher Site | Google Scholar

114. R. Perera, M. Khaliq, and R. J. Kuhn, “Closing the door on flaviviruses: entry as a target
for antiviral drug design,” Antiviral Research, vol. 80, no. 1, pp. 11–22, 2008.View at: Publisher
Site | Google Scholar

115. Y. Modis, S. Ogata, D. Clements, and S. C. Harrison, “Variable surface epitopes in the
crystal structure of dengue virus type 3 envelope glycoprotein,” Journal of Virology, vol. 79, no.
2, pp. 1223–1231, 2005.View at: Publisher Site | Google Scholar
116. R. de Alwis, M. Beltramello, W. B. Messer et al., “In-depth analysis of the antibody
response of individuals exposed to primary dengue virus infection,” PLoS Neglected Tropical
Diseases, vol. 5, no. 6, Article ID e1188, 2011.View at: Publisher Site | Google Scholar

117. W. B. Messer, R. de Alwis, B. L. Yount et al., “Dengue virus envelope protein domain
I/II hinge determines long-lived serotype-specific dengue immunity,” Proceedings of the
National Academy of Sciences of the United States of America, vol. 111, no. 5, pp. 1939–1944,
2014.View at: Publisher Site | Google Scholar

118. R. De Alwis, S. A. Smith, N. P. Olivarez et al., “Identification of human neutralizing

antibodies that bind to complex epitopes on dengue virions,” Proceedings of the National
Academy of Sciences of the United States of America, vol. 109, no. 19, pp. 7439–7444,
2012.View at: Publisher Site | Google Scholar

119. G. Fibriansah, K. D. Ibarra, T.-S. Ng et al., “Cryo-EM structure of an antibody that

neutralizes dengue virus type 2 by locking E protein dimers,” Science, vol. 349, no. 6243, pp. 88–
91, 2015.View at: Publisher Site | Google Scholar

120. S. Watanabe, K. W. K. Chan, J. Wang, L. Rivino, S.-M. Lok, and S. G. Vasudevan,

“Dengue virus infection with highly neutralizing levels of cross-reactive antibodies causes acute
lethal small intestinal pathology without a high level of viremia in mice,” Journal of Virology,
vol. 89, no. 11, pp. 5847–5861, 2015.View at: Publisher Site | Google Scholar

121. W. Dejnirattisai, A. Jumnainsong, N. Onsirisakul et al., “Cross-reacting antibodies

enhance dengue virus infection in humans,” Science, vol. 328, no. 5979, pp. 745–748, 2010.View
at: Publisher Site | Google Scholar

122. C. De La Guardia and R. Lleonart, “Progress in the identification of dengue virus

entry/fusion inhibitors,” BioMed Research International, vol. 2014, Article ID 825039, 13 pages,
2014.View at: Publisher Site | Google Scholar

123. K. Jessie, M. Y. Fong, S. Devi, S. K. Lam, and K. T. Wong, “Localization of dengue

virus in naturally infected human tissues, by immunohistochemistry and in situ
hybridization,” Journal of Infectious Diseases, vol. 189, no. 8, pp. 1411–1418, 2004.View
at: Publisher Site | Google Scholar

124. S.-J. L. Wu, G. Grouard-Vogel, W. Sun et al., “Human skin Langerhans cells are targets
of dengue virus infection,” Nature Medicine, vol. 6, no. 7, pp. 816–820, 2000.View at: Publisher
Site | Google Scholar
125. A. Molina-Cruz, L. Gupta, J. Richardson, K. Bennett, W. Black IV, and C. Barillas-
Mury, “Effect of mosquito midgut trypsin activity on dengue-2 virus infection and dissemination
in Aedes aegypti,” The American Journal of Tropical Medicine and Hygiene, vol. 72, no. 5, pp.
631–637, 2005.View at: Google Scholar

126. M. I. Salazar, J. H. Richardson, I. Sánchez-Vargas, K. E. Olson, and B. J. Beaty,

“Dengue virus type 2: replication and tropisms in orally infected Aedes aegypti
mosquitoes,” BMC Microbiology, vol. 7, article 9, 2007.View at: Publisher Site | Google Scholar

127. S. Swaminathan and N. Khanna, “Experimental dengue vaccines,” Molecular Vaccines:

From Prophylaxis to Therapy, vol. 1, pp. 135–151, 2013.View at: Publisher Site | Google
Scholar

128. J. Barniol, R. Gaczkowski, E. V. Barbato et al., “Usefulness and applicability of the

revised dengue case classification by disease: multi-centre study in 18 countries,” BMC
Infectious Diseases, vol. 11, article 106, 2011.View at: Publisher Site | Google Scholar

129. F. Narvaez, G. Gutierrez, M. A. Pérez et al., “Evaluation of the traditional and revised
WHO classifications of dengue disease severity,” PLoS Neglected Tropical Diseases, vol. 5, no.
11, Article ID e1397, 2011.View at: Publisher Site | Google Scholar

130. M. G. Guzman, L. Hermida, L. Bernardo, R. Ramirez, and G. Guillén, “Domain III of the
envelope protein as a dengue vaccine target,” Expert Review of Vaccines, vol. 9, no. 2, pp. 137–
147, 2010.View at: Publisher Site | Google Scholar

131. S.-W. Wan, C.-F. Lin, S. Wang et al., “Current progress in dengue vaccines,” Journal of
Biomedical Science, vol. 20, no. 1, article 37, 2013.View at: Publisher Site | Google Scholar

132. N. Bhamarapravati and Y. Sutee, “Live attenuated tetravalent dengue vaccine,” Vaccine,

vol. 18, supplement 2, pp. 44–47, 2000.View at: Publisher Site | Google Scholar

133. N. Bhamarapravati, S. Yoksan, T. Chayaniyayothin, S. Angsubphakorn, and A.

Bunyaratvej, “Immunization with a live attenuated dengue-2-virus candidate vaccine (16681-
PDK 53): clinical, immunological and biological responses in adult volunteers,” Bulletin of the
World Health Organization, vol. 65, no. 2, pp. 189–195, 1987.View at: Google Scholar

134. C. Balas, A. Kennel, F. Deauvieau et al., “Different innate signatures induced in human
monocyte-derived dendritic cells by wild-type dengue 3 virus, attenuated but reactogenic dengue
3 vaccine virus, or attenuated nonreactogenic dengue 1–4 vaccine virus strains,” Journal of
Infectious Diseases, vol. 203, no. 1, pp. 103–108, 2011.View at: Publisher Site | Google Scholar
135. W. Sun, D. Cunningham, S. S. Wasserman et al., “Phase 2 clinical trial of three
formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naïve adults,” Human
Vaccines, vol. 5, no. 1, pp. 33–40, 2009.View at: Publisher Site | Google Scholar

136. V. Watanaveeradej, S. Simasathien, A. Nisalak et al., “Safety and immunogenicity of a

tetravalent live-attenuated dengue vaccine in flavivirus-naive infants,” The American Journal of
Tropical Medicine and Hygiene, vol. 85, no. 2, pp. 341–351, 2011.View at: Publisher
Site | Google Scholar

137. S. J. Thomas, K. H. Eckels, I. Carletti et al., “A phase II, randomized, safety and
immunogenicity study of a re-derived, live-attenuated dengue virus vaccine in healthy
adults,” The American Journal of Tropical Medicine and Hygiene, vol. 88, no. 1, pp. 73–88,
2013.View at: Publisher Site | Google Scholar

138. K. Bauer, I. O. Esquilin, A. S. Cornier et al., “A phase II, randomized, safety and
immunogenicity trial of a re-derived, live-attenuated dengue virus vaccine in healthy children and
adults living in puerto rico,” The American Journal of Tropical Medicine and Hygiene, vol. 93,
no. 3, pp. 441–453, 2015.View at: Publisher Site | Google Scholar

139. S. S. Whitehead, B. Falgout, K. A. Hanley, J. E. Blaney Jr., L. Markoff, and B. R.

Murphy, “A live, attenuated dengue virus type 1 vaccine candidate with a 30-nucleotide deletion
in the 3′ untranslated region is highly attenuated and immunogenic in monkeys,” Journal of
Virology, vol. 77, no. 2, pp. 1653–1657, 2003.View at: Publisher Site | Google Scholar

140. S. S. Whitehead, “Development of TV003/TV005, a single dose, highly immunogenic

live attenuated dengue vaccine; what makes this vaccine different from the Sanofi-Pasteur
CYD™ vaccine ?” Expert Review of Vaccines, vol. 15, no. 4, 2015.View at: Publisher
Site | Google Scholar

141. B. D. Kirkpatrick, S. S. Whitehead, K. K. Pierce et al., “The live attenuated dengue

vaccine TV003 elicits complete protection against dengue in a human challenge model,” Science
Translational Medicine, vol. 8, no. 330, Article ID 330ra36, 2016.View at: Publisher
Site | Google Scholar

142. A. R. Precioso, R. Palacios, B. Thomé, G. Mondini, P. Braga, and J. Kalil, “Clinical

evaluation strategies for a live attenuated tetravalent dengue vaccine,” Vaccine, vol. 33, no. 50,
pp. 7121–7125, 2015.View at: Publisher Site | Google Scholar
143. F. Guirakhoo, R. Weltzin, T. J. Chambers et al., “Recombinant chimeric yellow fever-
dengue type 2 virus is immunogenic and protective in nonhuman primates,” Journal of Virology,
vol. 74, no. 12, pp. 5477–5485, 2000.View at: Publisher Site | Google Scholar

144. B. Guy, M. Saville, and J. Lang, “Development of sanofi pasteur tetravalent dengue
vaccine,” Human Vaccines, vol. 6, no. 9, pp. 696–705, 2010.View at: Publisher Site | Google
Scholar

145. C. Y.-H. Huang, S. Butrapet, K. R. Tsuchiya, N. Bhamarapravati, D. J. Gubler, and R. M.

Kinney, “Dengue 2 PDK-53 virus as a chimeric carrier for tetravalent dengue vaccine
development,” Journal of Virology, vol. 77, no. 21, pp. 11436–11447, 2003.View at: Publisher
Site | Google Scholar

146. J. E. Osorio, J. N. Brewoo, S. J. Silengo et al., “Efficacy of a tetravalent chimeric dengue

vaccine (DENVax) in cynomolgus macaques,” American Journal of Tropical Medicine and
Hygiene, vol. 84, no. 6, pp. 978–987, 2011.View at: Publisher Site | Google Scholar

147. J. E. Osorio, I. D. Velez, C. Thomson et al., “Safety and immunogenicity of a

recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy
adults in Colombia: a randomised, placebo-controlled, phase 1 study,” The Lancet Infectious
Diseases, vol. 14, no. 9, pp. 830–838, 2014.View at: Publisher Site | Google Scholar

148. Takeda. Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine
(TDV) in Healthy Children (TIDES), ClinicalTrials.gov, Bethesda, Md, USA, National Library of
Medicine, 2000, https://clinicaltrials.gov/ct2/show/NCT02747927.

149. R. Putnak, D. A. Barvir, J. M. Burrous et al., “Development of a purified, inactivated,

dengue-2 virus vaccine prototype in Vero cells: immunogenicity and protection in mice and
rhesus monkeys,” The Journal of Infectious Diseases, vol. 174, no. 6, pp. 1176–1184, 1996.View
at: Publisher Site | Google Scholar

150. J. R. Putnak, B.-A. Coller, G. Voss et al., “An evaluation of dengue type-2 inactivated,
recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque
model,” Vaccine, vol. 23, no. 35, pp. 4442–4452, 2005.View at: Publisher Site | Google Scholar

151. M. Simmons, T. Burgess, J. Lynch, and R. Putnak, “Protection against dengue virus by
non-replicating and live attenuated vaccines used together in a prime boost vaccination
strategy,” Virology, vol. 396, no. 2, pp. 280–288, 2010.View at: Publisher Site | Google Scholar

152. US Army Medical Research and Materiel Command, “Safety study of a vaccine (DENV-
1 PIV) to prevent dengue disease (DENV-1 PIV),” in ClinicalTrials.gov, National Library of
 Medicine (US), Bethesda, Md, USA, 2000, NLM Identifier:
NCT01502735, https://clinicaltrials.gov/ct2/show/NCT01502735.View at: Google Scholar

153. US Army Medical Research and Materiel Command, A Two-dose Primary Vaccination
Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults
(DPIV-001). In: ClinicalTrials.gov [Internet]. Bethesda, Md, USA, National Library of Medicine
(US). 2000- [cited 2016 May 13], NLM Identifier:
NCT01666652, https://clinicaltrials.gov/ct2/show/NCT01666652.

154. US Army Medical Research and Materiel Command, “A Two-dose Primary Vaccination
Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults
(in Puerto Rico) (DPIV-002),” ClinicalTrials.gov, Bethesda, Md, USA, National Library of
Medicine, NLM Identifier: NCT01702857,
2000, https://clinicaltrials.gov/ct2/show/NCT01702857.View at: Google Scholar

155. US Army Medical Research and Materiel Command, TDENV PIV and LAV Dengue
Prime-boost Strategy, ClinicalTrials.gov, Bethesda, Md, USA, National Library of Medicine
(US), NLM Identifier: NCT02239614, 2000, https://clinicaltrials.gov/ct2/show/NCT02239614.

156. D. E. Clements, B.-A. G. Coller, M. M. Lieberman et al., “Development of a recombinant

tetravalent dengue virus vaccine: immunogenicity and efficacy studies in mice and
monkeys,” Vaccine, vol. 28, no. 15, pp. 2705–2715, 2010.View at: Publisher Site | Google
Scholar

157. D. Govindarajan, S. Meschino, L. Guan et al., “Preclinical development of a dengue

tetravalent recombinant subunit vaccine: immunogenicity and protective efficacy in nonhuman
primates,” Vaccine, vol. 33, no. 33, pp. 4105–4116, 2015.View at: Publisher Site | Google
Scholar

158. S. B. Manoff, S. L. George, A. J. Bett et al., “Preclinical and clinical development of a

dengue recombinant subunit vaccine,” Vaccine, vol. 33, no. 50, pp. 7126–7134, 2015.View
at: Publisher Site | Google Scholar

159. Merck Sharp & Dohme Corp, Study of a Dengue Vaccine (V180) in Healthy Adults
(V180-001), ClinicalTrials.gov, Bethesda, Md, USA, National Library of Medicine (US), NLM
Identifier: NCT01477580, 2000, https://clinicaltrials.gov/ct2/show/NCT01477580.

160. M. Simmons, G. S. Murphy, and C. G. Hayes, “Short report: antibody responses of mice
immunized with a tetravalent dengue recombinant protein subunit vaccine,” The American
 Journal of Tropical Medicine and Hygiene, vol. 65, no. 2, pp. 159–161, 2001.View at: Google
Scholar

161. L. Hermida, R. Rodríguez, L. Lazo et al., “A fragment of the envelope protein from
dengue-1 virus, fused in two different sites of the meningococcal P64k protein carrier, induces a
functional immune response in mice,” Biotechnology and Applied Biochemistry, vol. 39, no. 1,
pp. 107–114, 2004.View at: Publisher Site | Google Scholar

162. L. Hermida, R. Rodríguez, L. Lazo et al., “A dengue-2 Envelope fragment inserted within
the structure of the P64k meningococcal protein carrier enables a functional immune response
against the virus in mice,” Journal of Virological Methods, vol. 115, no. 1, pp. 41–49, 2004.View
at: Publisher Site | Google Scholar

163. L. Hermida, L. J. Bernardo, M. Martín et al., “A recombinant fusion protein containing

the domain III of the dengue-2 envelope protein is immunogenic and protective in nonhuman
primates,” Vaccine, vol. 24, no. 16, pp. 3165–3171, 2006.View at: Google Scholar

164. J. R. Danko, C. G. Beckett, and K. R. Porter, “Development of dengue DNA

vaccines,” Vaccine, vol. 29, no. 42, pp. 7261–7266, 2011.View at: Publisher Site | Google
Scholar

165. C. G. Beckett, J. Tjaden, T. Burgess et al., “Evaluation of a prototype dengue-1 DNA

vaccine in a Phase 1 clinical trial,” Vaccine, vol. 29, no. 5, pp. 960–968, 2011.View at: Publisher
Site | Google Scholar

166. K. R. Porter, D. Ewing, L. Chen et al., “Immunogenicity and protective efficacy of a

vaxfectin-adjuvanted tetravalent dengue DNA vaccine,” Vaccine, vol. 30, no. 2, pp. 336–341,
2012.View at: Publisher Site | Google Scholar

167. K. Raviprakash, T. Luke, J. Doukas et al., “A dengue DNA vaccine formulated with
Vaxfectin® is well tolerated, and elicits strong neutralizing antibody responses to all four dengue
serotypes in New Zealand white rabbits,” Human Vaccines and Immunotherapeutics, vol. 8, no.
12, pp. 1764–1768, 2012.View at: Publisher Site | Google Scholar

168. US Army Medical Research and Materiel Command, Evaluation of the Safety and the
Ability of a DNA Vaccine to Protect Against Dengue Disease (TVDV), ClinicalTrials.gov,
Bethesda, Md, USA, National Library of Medicine (US), NLM Identifier: NCT01502358,
2000, https://clinicaltrials.gov/ct2/show/NCT01502358.

169. K. Raviprakash, D. Wang, D. Ewing et al., “A tetravalent dengue vaccine based on a

complex adenovirus vector provides significant protection in rhesus monkeys against all four
 serotypes of dengue virus,” Journal of Virology, vol. 82, no. 14, pp. 6927–6934, 2008.View
at: Publisher Site | Google Scholar

170. L. J. White, M. M. Parsons, A. C. Whitmore, B. M. Williams, A. de Silva, and R. E.

Johnston, “An immunogenic and protective alphavirus replicon particle-based dengue vaccine
overcomes maternal antibody interference in weanling mice,” Journal of Virology, vol. 81, no.
19, pp. 10329–10339, 2007.View at: Publisher Site | Google Scholar

171. S. Brandler, M. Lucas-Hourani, A. Moris et al., “Pediatric measles vaccine expressing a

dengue antigen induces durable serotype-specific neutralizing antibodies to dengue virus,” PLoS
Neglected Tropical Diseases, vol. 1, no. 3, article e96, 2007.View at: Publisher Site | Google
Scholar

172. D. H. Holman, D. Wang, K. Raviprakash et al., “Two complex, adenovirus-based

vaccines that together induce immune responses to all four dengue virus serotypes,” Clinical and
Vaccine Immunology, vol. 14, no. 2, pp. 182–189, 2007.View at: Publisher Site | Google Scholar

173. N. U. Raja, D. H. Holman, D. Wang et al., “Induction of bivalent immune responses by

expression of dengue virus type 1 and type 2 antigens from a single complex adenoviral
vector,” American Journal of Tropical Medicine and Hygiene, vol. 76, no. 4, pp. 743–751,
2007.View at: Google Scholar

174. R. Suzuki, E. R. Winkelmann, and P. W. Mason, “Construction and characterization of a

single-cycle chimeric flavivirus vaccine candidate that protects mice against lethal challenge with
dengue virus type 2,” Journal of Virology, vol. 83, no. 4, pp. 1870–1880, 2009.View at: Publisher
Site | Google Scholar

175. S. Mani, L. Tripathi, R. Raut et al., “Pichia pastoris-expressed dengue 2 envelope forms
virus-like particles without pre-membrane protein and induces high titer neutralizing
antibodies,” PLoS ONE, vol. 8, no. 5, Article ID e64595, 2013.View at: Publisher Site | Google
Scholar

176. T. J. Chambers, A. Nestorowicz, P. W. Mason, and C. M. Rice, “Yellow fever/Japanese

encephalitis chimeric viruses: construction and biological properties,” Journal of Virology, vol.
73, no. 4, pp. 3095–3101, 1999.View at: Google Scholar

177. F. Guirakhoo, K. Pugachev, Z. Zhang et al., “Safety and efficacy of chimeric yellow
fever-dengue virus tetravalent vaccine formulations in nonhuman primates,” Journal of Virology,
vol. 78, no. 9, pp. 4761–4775, 2004.View at: Publisher Site | Google Scholar
178. B. Guy, V. Barban, N. Mantel et al., “Evaluation of interferences between dengue
vaccine serotypes in a monkey model,” The American Journal of Tropical Medicine and Hygiene,
vol. 80, no. 2, pp. 302–311, 2009.View at: Google Scholar

179. S. B. Halstead, “Identifying protective dengue vaccines: guide to mastering an empirical

process,” Vaccine, vol. 31, no. 41, pp. 4501–4507, 2013.View at: Publisher Site | Google Scholar

180. F. Guirakhoo, S. Kitchener, D. Morrison et al., “Live attenuated chimeric yellow fever
dengue type 2 (ChimeriVax-DEN2) vaccine: phase I clinical trial for safety and immunogenicity:
effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4
dengue serotypes,” Human Vaccines, vol. 2, no. 2, pp. 60–67, 2006.View at: Google Scholar

181. D. Morrison, T. J. Legg, C. W. Billings, R. Forrat, S. Yoksan, and J. Lang, “A novel

tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in
flavivirus-naive adults,” The Journal of Infectious Diseases, vol. 201, no. 3, pp. 370–377,
2010.View at: Publisher Site | Google Scholar

182. R. Z. Capeding, I. A. Luna, E. Bomasang et al., “Live-attenuated, tetravalent dengue

vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled
phase I trial in the Philippines,” Vaccine, vol. 29, no. 22, pp. 3863–3872, 2011.View at: Publisher
Site | Google Scholar

183. G. H. Dayan, M. Thakur, M. Boaz, and C. Johnson, “Safety and immunogenicity of three
tetravalent dengue vaccine formulations in healthy adults in the USA,” Vaccine, vol. 31, no. 44,
pp. 5047–5054, 2013.View at: Publisher Site | Google Scholar

184. A. Sabchareon, D. Wallace, C. Sirivichayakul et al., “Protective efficacy of the

recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a
randomised, controlled phase 2b trial,” The Lancet, vol. 380, no. 9853, pp. 1559–1567,
2012.View at: Publisher Site | Google Scholar

185. A. Ghosh and L. Dar, “Dengue vaccines: challenges, development, current status and
prospects,” Indian Journal of Medical Microbiology, vol. 33, no. 1, pp. 3–15, 2015.View
at: Publisher Site | Google Scholar

186. S. B. Halstead and P. K. Russell, “Protective and immunological behavior of chimeric

yellow fever dengue vaccine,” Vaccine, vol. 34, no. 14, pp. 1643–1647, 2016.View at: Publisher
Site | Google Scholar

187. L. Á. Villar, D. M. Rivera-Medina, J. L. Arredondo-García et al., “Safety and

immunogenicity of a recombinant tetravalent dengue vaccine in 9-16 year olds: a randomized,
 controlled, phase II trial in Latin America,” Pediatric Infectious Disease Journal, vol. 32, no. 10,
pp. 1102–1109, 2013.View at: Publisher Site | Google Scholar

188. M. R. Capeding, N. H. Tran, S. R. S. Hadinegoro et al., “Clinical efficacy and safety of a

novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-
masked, placebo-controlled trial,” The Lancet, vol. 384, no. 9951, pp. 1358–1365, 2014.View
at: Publisher Site | Google Scholar

189. S. R. Hadinegoro, J. L. Arredondo-García, M. R. Capeding et al., “Efficacy and long-

term safety of a dengue vaccine in regions of endemic disease,” The New England Journal of
Medicine, vol. 373, no. 13, pp. 1195–1206, 2015.View at: Publisher Site | Google Scholar

190. L. Villar, G. H. Dayan, J. L. Arredondo-García et al., “Efficacy of a tetravalent dengue

vaccine in children in Latin America,” The New England Journal of Medicine, vol. 372, no. 2, pp.
113–123, 2015.View at: Publisher Site | Google Scholar

191. A. Wilder-Smith and D. J. Gubler, “Dengue vaccines at a crossroad: despite modest ef

cacy, a newly developed vaccine may be key for controlling dengue,” Science, vol. 350, no. 6261,
pp. 626–627, 2015.View at: Publisher Site | Google Scholar

192. K. W. K. Chan, S. Watanabe, R. Kavishna, S. Alonso, and S. G. Vasudevan, “Animal

models for studying dengue pathogenesis and therapy,” Antiviral Research, vol. 123, pp. 5–14,
2015.View at: Publisher Site | Google Scholar

193. R. M. Zellweger and S. Shresta, “Mouse models to study dengue virus immunology and
pathogenesis,” Frontiers in Immunology, vol. 5, article 151, 2014.View at: Publisher
Site | Google Scholar

194. D. Weiskopf, M. A. Angelo, E. L. De Azeredo et al., “Comprehensive analysis of dengue

virus-specific responses supports an HLA-linked protective role for CD8 + T cells,” Proceedings
of the National Academy of Sciences of the United States of America, vol. 110, no. 22, pp.
E2046–E2053, 2013.View at: Publisher Site | Google Scholar

195. D. Weiskopf and A. Sette, “T-cell immunity to infection with dengue virus in
humans,” Frontiers in Immunology, vol. 5, article 93, 2014.View at: Publisher Site | Google
Scholar

196. N. Modhiran, D. Watterson, D. A. Muller et al., “Dengue virus NS1 protein activates
cells via Toll-like receptor 4 and disrupts endothelial cell monolayer integrity,” Science
Translational Medicine, vol. 7, no. 304, Article ID 304ra142, 2015.View at: Publisher
Site | Google Scholar
197. R. P. Beatty, H. Puerta-Guardo, S. S. Killingbeck, D. Glasner, and E. Harris, “Dengue
virus NS1 triggers endothelial permeability and vascular leak that is prevented by NS1
vaccination,” Science Translational Medicine, vol. 7, no. 304, Article ID 304ra141, 2015.